RLRoberto Liserre

Roberto Liserre

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Roberto Liserre has a total of 16 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Radiotherapy in low-grade glioma adult patients: a retrospective survival and neurocognitive toxicity analysis

    by Michela Buglione, Sara Pedretti, Stefano Gipponi, Alice Todeschini, Ludovica Pegurri, Loredana Costa, Laura Donadoni, Salvatore Grisanti, Marco Fontanella, Roberto Liserre, et al.

    Purpose The treatment of low-grade glioma is still debated. Surgery is the first-line approach, and the correct timing of radiation therapy has not yet been defined since “early” radiation therapy improves relapse-free survival but not overall survival. Since a longer progression-free survival is desirable, the main issue related to radiotherapy is the incidence of late neurocognitive toxicity. Materials and methods Ninety-five patients with low-grade glioma were consecutively treated with early (within 3 months) or late (at disease progression) post-surgical radiation therapy. Clinical and therapeutic factors were entered into the analysis overall (OS) and progression-free (PFS) survival, and the distribution in two accrual periods identified based on the evolution of imaging procedures and radiotherapy techniques were compared. For 6/18 long survivors (LS) without evidence of disease, neurocognitive evaluation was obtained and the dose to the hippocampus region was retrospectively calculated. Results Univariate analysis of OS showed a statistically significant advantage for grade 1 and oligodendroglioma histology, better performance status [Karnofsky index (KI)], age <40 years, radical surgery, no steroid treatment; PFS was significantly related with younger age, better KI and “early” radiotherapy. Multivariate analysis of OS confirmed the significance of all variables except surgery; for PFS, only “early” radiotherapy and better KI retained significance. Memory impairment was evident in 4/6 of the LS tested; quality of life was good and executive functions were normal. Conclusion Radiotherapy remains an essential component in the treatment of low-grade glioma. Prospective studies are needed to evaluate the relative contributions of the disease itself and of surgery, radiation and chemotherapy to long-term neurocognitive damage.


  • Open Access

    Retreatment of recurrent adult medulloblastoma with radiotherapy: a case report and review of the literature

    by Michela Buglione, Luca Triggiani, Salvatore Grisanti, Roberto Liserre, Luciano Buttolo, Stefano Gipponi, Fausta Bonetti, Alice Todeschini, Luigi Spiazzi, Stefano Maria Magrini

    Medulloblastoma, the most frequent brain tumor in childhood, also occurs with a wide range of characteristics in adult patients. Late relapse is common in adult medulloblastoma, and the overall survival of relapsed patients usually ranges from 12 to 15 months. Treatment at recurrence is still debated and after reoperation includes stereotactic or normofractionated radiotherapy, and high-dose chemotherapy with autologous bone marrow transplantation.